These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15956976)

  • 1. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
    Levitt NC; Propper DJ; Madhusudan S; Braybrooke JP; Echeta C; Te Poele R; Davies SL; Flanagan E; Hickson ID; Joel S; Ganesan TS
    Br J Cancer; 2005 Jul; 93(1):60-9. PubMed ID: 15956976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
    Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
    Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
    Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
    Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
    Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
    Rose PG; Markman M; Bell JG; Fusco NL
    Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
    Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
    Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
    Herben VM; ten Bokkel Huinink WW; Dubbelman AC; Mandjes IA; Groot Y; van Gortel-van Zomeren DM; Beijnen JH
    Br J Cancer; 1997; 76(11):1500-8. PubMed ID: 9400949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
    Stein SM; Tiersten A; Hochster HS; Blank SV; Pothuri B; Curtin J; Shapira I; Levinson B; Ivy P; Joseph B; Guddati AK; Muggia F
    Int J Gynecol Cancer; 2013 Nov; 23(9):1577-82. PubMed ID: 24172094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
    Elkas JC; Winter WE; Chernofsky MR; Sunde J; Bidus MA; Bernstein S; Rose GS
    Gynecol Oncol; 2007 Feb; 104(2):422-7. PubMed ID: 16996118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
    Miller AA; Niell HB
    Lung Cancer; 2001; 33(2-3):241-8. PubMed ID: 11551419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
    Braybrooke JP; Levitt NC; Joel S; Davis T; Madhusudan S; Turley H; Wilner S; Harris AL; Talbot DC
    Clin Cancer Res; 2003 Oct; 9(13):4682-8. PubMed ID: 14581337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.